Cabenuva

(Cabotegravir/rilpivirine)

Cabenuva

Drug updated on 11/15/2023

Dosage FormInjection (intramuscular; 600 mg/3mL, 400 mg/2mL)
Drug ClassAntiviral combinations
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.